



PATENT  
Docket No.: 200701/1061

Docket No.: 200701/1061

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Schultz et al.

Serial No. : 09/757,992

Cnfrm. No. : 8517

Filed : January 10, 2001

For : DETECTION OF SINGLE NUCLEOTIDE  
POLYMORPHISMS

Examiner:  
To Be Assigned

Art Unit:  
1645

## PRELIMINARY AMENDMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

### Box: Missing Parts

Dear Sir:

Please amend the above-identified application as follows:

In the Abstract of the Disclosure:

Please replace the Abstract of the Disclosure on page 54 with the following:

The present invention relates to a method of detecting single nucleotide polymorphisms by blending a target nucleic molecule, a oligonucleotide primer, a nucleic acid polymerizing enzyme, and nucleotide analogs, each type being present in a first amount, to form an extension solution where the oligonucleotide primer is hybridized to the target nucleic acid molecule to form a primed target nucleic acid molecule and the nucleic acid polymerizing enzyme is positioned to add nucleotide analogs to the primed target nucleic acid molecule at an active site. The oligonucleotide primer in the extension solution is extended by using the nucleic acid polymerizing enzyme to add a nucleotide analog to the oligonucleotide primer at the active site. The amounts of each type of the nucleotide analogs in the extension solution after the extending step are then determined where each type is

present in a second amount. The type of nucleotide analog where the first and second amounts differ is identified as the nucleotide added to the oligonucleotide primer at the active site.

### REMARKS

To shorten the length of the Abstract of the Disclosure, applicants have replaced the filed version of the Abstract with a shorter version thereof. Pursuant to 37 CFR § 1.21, attached as an Appendix is a version of the Abstract of the Disclosure with markings to show changes made.

Applicants also direct entry into the application of the accompanying sequence listing.


Respectfully submitted,

Date: June 8, 2001



Michael L. Goldman  
Registration No. 30,727

Nixon Peabody LLP  
Clinton Square, P.O. Box 31051  
Rochester, New York 14603  
Telephone: (716) 263-1304  
Facsimile: (716) 263-1600

Certificate of Mailing - 37 CFR 1.8 (a)	
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date below.	
6/8/01	
Date	Wendy L. Harrold

## Appendix

### Version of Amended Claims With Markings to Show Changes Made

In reference to the amendments made herein to the Abstract of the Disclosure, additions appear as underlined text, while deletions appear as bracketed text, as indicated below:

#### In the Abstract of the Disclosure:

[The present invention relates to a method of detecting single nucleotide polymorphisms by providing a target nucleic acid molecule, an oligonucleotide primer complementary to a portion of the target nucleic acid molecule, a nucleic acid polymerizing enzyme, and a plurality of types of nucleotide analogs. The target nucleic molecule, the oligonucleotide primer, the nucleic acid polymerizing enzyme, and the nucleotide analogs, each type being present in a first amount, are blended to form an extension solution where the oligonucleotide primer is hybridized to the target nucleic acid molecule to form a primed target nucleic acid molecule and the nucleic acid polymerizing enzyme is positioned to add nucleotide analogs to the primed target nucleic acid molecule at an active site. The oligonucleotide primer in the extension solution is extended by using the nucleic acid polymerizing enzyme to add a nucleotide analog to the oligonucleotide primer at the active site. This forms an extended oligonucleotide primer, wherein the nucleotide analog being added is complementary to the nucleotide of the target nucleic acid molecule at the active site. The amounts of each type of the nucleotide analogs in the extension solution after the extending step are then determined where each type is present in a second amount. The first and second amounts of each type of the nucleotide analog are compared. The type of nucleotide analog where the first and second amounts differ as the nucleotide added to the oligonucleotide primer at the active site is then identified. The steps of extending, determining the amounts of each type of the nucleotide analog, comparing the first and second amounts of the nucleotide analog, and said identifying the type of nucleotide analog added may be repeated, either after repeating the blending with the extended oligonucleotide primer or after determining the amounts of each type of dideoxynucleotide or dideoxynucleotide analog remaining in the extension solution as the new first amount. As a result, the nucleotide at the active site of the target nucleic acid molecule is determined. Also disclosed is an apparatus and composition for carrying out this method.]

The present invention relates to a method of detecting single nucleotide polymorphisms by blending a target nucleic molecule, a oligonucleotide primer, a nucleic acid polymerizing enzyme, and nucleotide analogs, each type being present in a first amount, to form an extension solution where the oligonucleotide primer is hybridized to the target nucleic acid molecule to form a primed target nucleic acid molecule and the nucleic acid polymerizing enzyme is positioned to add nucleotide analogs to the primed target nucleic acid molecule at an active site. The oligonucleotide primer in the extension solution is extended by using the nucleic acid polymerizing enzyme to add a nucleotide analog to the oligonucleotide primer at the active site. The amounts of each type of the nucleotide analogs in the extension solution after the extending step are then determined where each type is present in a second amount. The type of nucleotide analog where the first and second amounts differ is identified as the nucleotide added to the oligonucleotide primer at the active site.

09757992-061101